November 2, 2017
Lund, Sweden, 08.00 CET, 2 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Interim Report January – September 2017. Q3 Net sales increased by 23% FINANCIAL HIGHLIGHTS...
Lund, Sweden, 18:00 CET 31st October 2017 – During October, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31st October 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,900,591. For more information contact: Richard Davies, CEO Tel:...
EB8018 is an oral small molecule targeting the host-microbiome interaction by blocking FimH   PARIS and CAMBRIDGE, Massachusetts, October 27, 2017 /PRNewswire/ — ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its lead candidate EB8018, a small molecule designed to block...
Saint-Priest, France, October 27, 2017 – Biom’Up, specialist of surgical hemostasis, today provides a regulatory update regarding the United States Food and Drug Administration’s (FDA) review of the company’s Premarket Approval (PMA) application for its HEMOBLASTTM Bellows. The FDA conducted a PMA pre-approval inspection at the Biom’up Saint Priest, France, manufacturing facility. The four-day Premarket...


How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020
A 60-year-old’s muscles aren’t old at all
23. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge